Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1255 daily bars · split adjusted
Current price $14.96
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Aug 17, 26 |
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Jun 2, 26 | Bartholdson John A. | director, 10 percent owner: | M-Exempt | 32,282 | — |
Daily · Wilder smoothing
| Canaccord Genuity |
| maintain |
| Buy |
| Buy |
| Aug 17, 26 | Cantor Fitzgerald | maintain | Overweight | Overweight |
| Jun 30, 26 | Barrington Research | maintain | Outperform | Outperform |
| Jun 16, 26 | Canaccord Genuity | maintain | Buy | Buy |
| May 22, 26 | Barrington Research | maintain | Outperform | Outperform |
| Mar 6, 26 | Barrington Research | maintain | Outperform | Outperform |
| Mar 6, 26 | Craig-Hallum | maintain | Buy | Buy |
| Mar 17, 25 | Canaccord Genuity | maintain | Buy | Buy |
| Dec 17, 24 | JP Morgan | upgrade | Underweight | Neutral |
| Jun 3, 26 |
| Bartholdson John A. |
| director, 10 percent owner: |
| A-Award |
| 25,146 |
| — |
| Jun 2, 26 | Bartholdson John A. | director, 10 percent owner: | M-Exempt | 32,282 | — |
| Jun 2, 26 | Sutter Martin P | director, 10 percent owner: | M-Exempt | 32,282 | — |
| Jun 3, 26 | Sutter Martin P | director, 10 percent owner: | A-Award | 25,146 | — |
| Jun 2, 26 | Sutter Martin P | director, 10 percent owner: | M-Exempt | 32,282 | — |
| Jun 2, 26 | Stalnecker Susan M | director | M-Exempt | 32,282 | — |
| Jun 3, 26 | Stalnecker Susan M | director | A-Award | 25,146 | — |
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 65.88 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 96.47 | Oscillator | Sell |
| Williams %R (14) | -5.43 | Oscillator | Sell |
| MACD (12, 26, 9) | 0.28 (Hist 0.19) | Oscillator | Strong Buy |
| Average Directional Index (14) | 17.02 (+DI 36.3 / -DI 16.3) | Trend | Neutral |
| EMA 20 | 13.80 | MA | Strong Buy |
| SMA 20 | 13.64 | MA | Strong Buy |
| EMA 50 | 13.43 | MA | Strong Buy |
| SMA 50 | 13.69 | MA | Strong Buy |
| SMA 200 | 10.74 | MA | Strong Buy |
FY2025 · 10-K disclosure
FY2025 · 10-K disclosure
Stock news · updated daily
On October 12, 2026, Bioventus Inc (BVS) shares rose 3.6% today, currently priced at $13.53. This move comes amid a 52-week range of $6.46 to $15.89.GF Valueâ¢
Bioventus (NASDAQ: BVS - Get Free Report) and Kestra Medical Technologies (NASDAQ: KMTS - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability and earnings. Risk and Volatility Bioventus has a beta
RxSight (NASDAQ: RXST - Get Free Report) and Bioventus (NASDAQ: BVS - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, valuation, institutional ownership, dividends and profitability. Analyst Ratings This is a summary of recent recommendations
Bioventus leverages cash from established products to reduce debt and fund commercial expansion, supporting a bullish outlook. BVS benefits from improved financing flexibility, with a term loan maturity extended to 2030 and a 75 bps interest margin reduction. Execution focus is on demonstrating sustained cash flows, successful new product adoption, and repeat physician usage, not just early launch revenue.
Here is how Bioventus (BVS) and Amneal Pharmaceuticals (AMRX) have performed compared to their sector so far this year.
A rate hike could keep markets volatile, making BVS, CNC, AMRX and CRON healthcare stocks to consider as inflation stays elevated.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Bioventus Inc. (BVS) Q2 2026 Earnings Call Transcript
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 5, 2026 | 0.22 | 0.22 | Beat 1.7% | $153.2M |
| May 6, 2026 | 0.09 | 0.15 | Beat 66.7% | $132.1M |
| Mar 5, 2026 | 0.22 | 0.24 | Beat 9.1% | $157.9M |
| Nov 4, 2025 | 0.22 | 0.15 | Miss -30.2% | $138.7M |
| Aug 6, 2025 | 0.22 | 0.21 | Miss -4.5% | $147.7M |
| May 6, 2025 | 0.06 | 0.08 | Beat 33.3% | $123.9M |
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 10-Q | Aug 5, 2026 | 2026-08-05 07:43:20 | View |
| 8-K | Aug 5, 2026 | 2026-08-05 07:40:11 | View |
| SC 13G | Jul 27, 2026 | 2026-07-27 16:25:25 | View |
| 4 | Jun 4, 2026 | 2026-06-04 17:06:35 | View |
| 4 | Jun 4, 2026 | 2026-06-04 16:48:01 | View |
| 4 | Jun 4, 2026 | 2026-06-04 16:47:48 | View |
| 4 | Jun 4, 2026 | 2026-06-04 16:47:35 | View |
| 4 | Jun 4, 2026 | 2026-06-04 16:47:18 | View |
| 4 | Jun 4, 2026 | 2026-06-04 16:47:04 | View |
| 4 | Jun 4, 2026 | 2026-06-04 16:46:43 | View |
Proxy statement (DEF 14A) disclosures
TTM vs. 5-year historical average (annual ratios)
| Metric | BVS | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | 18.6x | 6.5x · sector 20.7x | In line |
| Forward P/E (FY26E) | 19.2x | EPS est. 0.78 | In line |
| Price / Book | 4.4x | 2.2x | Elevated |
| Price / Sales | 1.8x | 0.9x | Elevated |
| EV / EBITDA | 12.1x | 3.9x | Elevated |
| Return on equity | 28.4% | — | Top tier |
| Gross margin | 68.0% | 66.8% | In line |
| Debt / Equity | 1.16 | 1.66 | Moderate |
| Piotroski / Altman Z | 8/9 | Z 2.27 | Grey zone |
Discounted cash flow model